UEGW 2020: Replacing other types of biologics or other anti-TNF antibodies is the most effective strategy against pharmaceutical antibodies.

At the 2020 European Digestive Disease Week (UEGW) online meeting, a study showed that in patients with inflammatory bowel disease (IBD), anti-tumor necrosis factor (TNF) antibodies are treated with anti-drug-resistant antibodies (ADA) and then switched to another TNF inhibitor or another type of biologic agent, which is the most effective way to help patients alleviate the disease.
photo source: Suzanne Anjie, M.D., University of Amsterdam Medical Center, Netherlands, says that while there are a number of treatments that can limit the emergence of ADA, there has been no comparison of the improved efficacy of these methods.
researchers analyzed data on 210 IBD patients treated in their hospitals between 2004 and 2019.
all patients had a higher ADA water level of 12 AU/ml for inflixi monoantigen or Adamo monoantigen.
the majority of patients in the study had Crohn's disease, and the majority of patients (n s 115) were treated with inflixi monoantigen.
chart shows that eight different strategies have been adopted for ADA: (1) keep the same dose of the same anti-TNF drug (20%) ;(2) continue to take the same anti-TNF drug but increase the dose (20%) ;(3) to switch to other anti-TNF drugs (20%) ;(4) to start or Optimize immunomodulant therapy (11%) ;(5) Optimize immunomodulation therapy and take a higher dose of the same TNF inhibitor (6%) ;(6) to completely stop using biologics (14%) ;(7) and switch to another class of biologics (5%) ;(8) for surgery.
results show that replacing a patient's biologics, whether in another category or another anti-TNF inhibitor, can most significantly alleviate clinical symptoms within one year.
.